Literature DB >> 2537066

Tamoxifen withdrawal response. Report of a case.

C P Belani1, P Pearl, N O Whitley, J Aisner.   

Abstract

A postmenopausal patient with breast cancer with a left infrahilar lung mass was treated with tamoxifen. She became asymptomatic, but after having stable disease for eight months, she developed progressive increase in the size of the mass necessitating tamoxifen withdrawal. Complete resolution of the mass occurred following withdrawal of tamoxifen. Withdrawal responses, though known to occur with additive hormonal treatment, especially complete regression of metastatic disease as seen in our patient, is not widely recognized. Thus, when clinically possible, patients should be observed off treatment for up to six weeks, before initiating a new therapeutic modality.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2537066

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  10 in total

1.  Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.

Authors:  Xiaonan Hou; Fei Huang; Luciana F Macedo; Sean C Harrington; Karen A Reeves; Ann Greer; Friedrich Graf Finckenstein; Angela Brodie; Marco M Gottardis; Joan M Carboni; Paul Haluska
Journal:  Cancer Res       Date:  2011-10-31       Impact factor: 12.701

2.  Tamoxifen-stimulated growth of breast cancer due to p21 loss.

Authors:  Abde M Abukhdeir; Michele I Vitolo; Pedram Argani; Angelo M De Marzo; Bedri Karakas; Hiroyuki Konishi; John P Gustin; Josh Lauring; Joseph P Garay; Courtney Pendleton; Yuko Konishi; Brian G Blair; Keith Brenner; Elizabeth Garrett-Mayer; Hetty Carraway; Kurtis E Bachman; Ben Ho Park
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-27       Impact factor: 11.205

3.  Effects of tamoxifen on human breast cancer cells in vitro.

Authors:  W E Simon; G Trams; F Hölzel
Journal:  Arch Gynecol Obstet       Date:  1993       Impact factor: 2.344

4.  Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice.

Authors:  D M Wolf; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

5.  The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain.

Authors:  D M Wolf; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 6.  Human breast cancer cell line xenografts as models of breast cancer. The immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines.

Authors:  R Clarke
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

Review 7.  Animal models of breast cancer: their diversity and role in biomedical research.

Authors:  R Clarke
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

8.  Clinical relevance of "withdrawal therapy" as a form of hormonal manipulation for breast cancer.

Authors:  Amit Agrawal; John F R Robertson; K L Cheung
Journal:  World J Surg Oncol       Date:  2011-09-09       Impact factor: 2.754

9.  Bringing estrogen receptors under control.

Authors:  K B Horwitz
Journal:  Breast Cancer Res       Date:  1999-08-27       Impact factor: 6.466

10.  Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy.

Authors:  Y Chavarri-Guerra; M J Higgins; J Szymonifka; T Cigler; P Liedke; A Partridge; J Ligibel; S E Come; D Finkelstein; P D Ryan; P E Goss
Journal:  Br J Cancer       Date:  2014-09-18       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.